Suleiman A. Massarweh,M.D.
Associate Professor
Suleiman A. Massarweh, MD
Associate Professor of Medicine
Clnical Interests: Breast Cancer
I.Office Address:
Office Address: Markey Cancer Center 800 Rose St. CC452 Lexington, Ky. 40536
Telephone: 859.257.3608
Fax: 859.257.7715
Email: massarweh@uky.edu
II.State Licensures and Certifications:
1999: Internal Medicine
2002: Hematology
2002: Medical Oncology
Active Licenses: Texas and Kentucky
III. Education:
1998-1994: M.B.,B.S.
University of Jordan Medical School
1994-1999: Internal Medicine Resident
Al-Nadim, Madaba, Jordan and Baylor College of Medicine
1999-2003: Hematology, Bone Marrow, and Oncology Fellowship
Baylor College of Medicine
Houston, TX
IV. Professional Experience
2006-present: Assistant Professor
University of Kentkcy, Markey Cancer Center
Division of Medical Oncology
2003-2005: Faculty
King Hussein Cancer Center (NCI sponsored)
Amman- Jordan
September 2004 -August 2005: Leader, Breast Cancer Services
1. Established first Breast CA multidisciplinary program in Jordan
2. Established Breast Cancer Treatment and Reporting guidelines
V. Committees and Memberships:
2008: Radiation Department 6-year review committee
2006-present: Protocol Review Committee
2004-2005: Breast Center Committee, Head
2004-2005: Institutional Review Board, Member
2004-2005: Performance Improvement Committee, Member
Member, American Society of Clinical Oncology (ASCO)
VI. Research and Publications:
Trials:
1.Phase II Study of Adding the Multikinase Inhibitor Sorafenib (NEXAVARŽ) to existing Endocrine Therapy in Patients with Advanced Breast Cancer”. Investigator-Initiated
Clinical Trials.gov ID: NCT00525161
Role: Principal investigator and trial sponsor
Trial sponsor trial.from Bayer, $281, 464
Grant: $281,464. Awarded by the investigator initiated program of BAYER
2. Phase II study of combined fulvestrant and RAD001 in metastatic breast cancer after aromatase inhibitor failure”. Investigator-Initiated
Clinical Trials.gov ID: NCT00570921
Role: Principal investigator and trial sponsor
Investigational New Drug Holder (IND), IND number: 79,103
Grant: $308,014. Awarded by the investigator-initiated program of NOVARTIS
Publications:
Morgan J, Massarweh S.: The role of ovarian suppression in the adjuvant therapy of premenopausal women with ER-positive breast cancer: A commentary on the EBCTCG overview analysis”. The American Journal of Hematology/Oncology, October 2007 supplement. Invited commentary
Massarweh S, Osborne CK, Creighton C, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, and Schiff R.: Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classical estrogen receptor genomic function”. Cancer Res 2008 February 1; 68: (3):826-833.
Creighton C, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck S, Osborne CK, and Rachel Schiff.: Development of resistance to targeted therapies transforms the clinically-defined molecular profile subtype of breast tumor xenografts.” Cancer Research, 2008 September 15; 68: (18):7493-7501.
Sapp C, Abdeen G, kamona A, and Massarweh S.: Complete radiologic resolution of leptomeningeal breast cancer involvement after systemic chemotherapy with weekly docetaxel”. Submitted
* For a complete list of current and past funding, advisory board positions, and publications, please e-mail Meredith Boarman at mtboar2@uky.edu.
|
